Cargando…

Beta-glucans in the treatment of diabetes and associated cardiovascular risks

Diabetes mellitus is characterized by high blood glucose level with typical manifestations of thirst, polyuria, polydipsia, and weight loss. It is caused by defects in insulin-mediated signal pathways, resulting in decreased glucose transportation from blood into muscle and fat cells. The major risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jiezhong, Raymond, Kenneth
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663451/
https://www.ncbi.nlm.nih.gov/pubmed/19337540
_version_ 1782165898185932800
author Chen, Jiezhong
Raymond, Kenneth
author_facet Chen, Jiezhong
Raymond, Kenneth
author_sort Chen, Jiezhong
collection PubMed
description Diabetes mellitus is characterized by high blood glucose level with typical manifestations of thirst, polyuria, polydipsia, and weight loss. It is caused by defects in insulin-mediated signal pathways, resulting in decreased glucose transportation from blood into muscle and fat cells. The major risk is vascular injury leading to heart disease, which is accelerated by increased lipid levels and hypertension. Management of diabetes includes: control of blood glucose level and lipids; and reduction of hypertension. Dietary intake of beta-glucans has been shown to reduce all these risk factors to benefit the treatment of diabetes and associated complications. In addition, beta-glucans also promote wound healing and alleviate ischemic heart injury. However, the mechanisms behind the effect of beta-glucans on diabetes and associated complications need to be further studied using pure beta-glucan.
format Text
id pubmed-2663451
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-26634512009-04-01 Beta-glucans in the treatment of diabetes and associated cardiovascular risks Chen, Jiezhong Raymond, Kenneth Vasc Health Risk Manag Review Diabetes mellitus is characterized by high blood glucose level with typical manifestations of thirst, polyuria, polydipsia, and weight loss. It is caused by defects in insulin-mediated signal pathways, resulting in decreased glucose transportation from blood into muscle and fat cells. The major risk is vascular injury leading to heart disease, which is accelerated by increased lipid levels and hypertension. Management of diabetes includes: control of blood glucose level and lipids; and reduction of hypertension. Dietary intake of beta-glucans has been shown to reduce all these risk factors to benefit the treatment of diabetes and associated complications. In addition, beta-glucans also promote wound healing and alleviate ischemic heart injury. However, the mechanisms behind the effect of beta-glucans on diabetes and associated complications need to be further studied using pure beta-glucan. Dove Medical Press 2008-12 /pmc/articles/PMC2663451/ /pubmed/19337540 Text en © 2008 Chen and Raymond, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Chen, Jiezhong
Raymond, Kenneth
Beta-glucans in the treatment of diabetes and associated cardiovascular risks
title Beta-glucans in the treatment of diabetes and associated cardiovascular risks
title_full Beta-glucans in the treatment of diabetes and associated cardiovascular risks
title_fullStr Beta-glucans in the treatment of diabetes and associated cardiovascular risks
title_full_unstemmed Beta-glucans in the treatment of diabetes and associated cardiovascular risks
title_short Beta-glucans in the treatment of diabetes and associated cardiovascular risks
title_sort beta-glucans in the treatment of diabetes and associated cardiovascular risks
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663451/
https://www.ncbi.nlm.nih.gov/pubmed/19337540
work_keys_str_mv AT chenjiezhong betaglucansinthetreatmentofdiabetesandassociatedcardiovascularrisks
AT raymondkenneth betaglucansinthetreatmentofdiabetesandassociatedcardiovascularrisks